Skip to main content
Top
Published in: BMC Cancer 1/2004

Open Access 01-12-2004 | Research article

BAG-1 haplo-insufficiency impairs lung tumorigenesis

Authors: Rudolf Götz, Boris W Kramer, Guadalupe Camarero, Ulf R Rapp

Published in: BMC Cancer | Issue 1/2004

Login to get access

Abstract

Background

BAG-1 is a multifunctional co-chaperone of heat shock proteins (Hsc70/Hsp70) that is expressed in most cells. It interacts with Bcl-2 and Raf indicating that it might connect protein folding with other signaling pathways. Evidence that BAG-1 expression is frequently altered in human cancers, in particular in breast cancer, relative to normal cells has been put forward but the notion that overexpression of BAG-1 contributes to poor prognosis in tumorigenesis remains controversial.

Methods

We have evaluated the effect of BAG-1 heterozygosity in mice in a model of non-small-cell lung tumorigenesis with histological and molecular methods. We have generated mice heterozygous for BAG-1, carrying a BAG-1 null allele, that in addition express oncogenic, constitutively active C-Raf kinase (SP-C C-Raf BxB) in type II pneumocytes. SP-C C-Raf BxB mice develop multifocal adenomas early in adulthood.

Results

We show that BAG-1 heterozygosity in mice impairs C-Raf oncogene-induced lung adenoma growth. Lung tumor initiation was reduced by half in BAG-1 heterozygous SP-C C-Raf BxB mice compared to their littermates. Tumor area was reduced by 75% in 4 month lungs of BAG-1 haploinsufficient mice compared to mice with two BAG-1 copies. Whereas BAG-1 heterozygosity did not affect the rate of cell proliferation or signaling through the mitogenic cascade in adenoma cells, it increased the rate of apoptosis.

Conclusion

Reduced BAG-1 expression specifically targets tumor cells to apoptosis and impairs tumorigenesis. Our data implicate BAG-1 as a key player in oncogenic transformation by Raf and identify it as a potential molecular target for cancer treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: A novel Bcl-2- binding protein with anti-cell death activity. Cell. 1995, 80: 279-284. 10.1016/0092-8674(95)90410-7.CrossRefPubMed Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: A novel Bcl-2- binding protein with anti-cell death activity. Cell. 1995, 80: 279-284. 10.1016/0092-8674(95)90410-7.CrossRefPubMed
2.
go back to reference Wang HG, Takayama S, Rapp UR, Reed JC: Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA. 1996, 93: 7063-7068. 10.1073/pnas.93.14.7063.CrossRefPubMedPubMedCentral Wang HG, Takayama S, Rapp UR, Reed JC: Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA. 1996, 93: 7063-7068. 10.1073/pnas.93.14.7063.CrossRefPubMedPubMedCentral
3.
go back to reference Townsend PA, Cutress RI, Sharp A, Brimmell M, Packham G: BAG-1: a multifunctional regulator of cell growth and survival. Biochim Biophys Acta. 2003, 1603: 83-98.PubMed Townsend PA, Cutress RI, Sharp A, Brimmell M, Packham G: BAG-1: a multifunctional regulator of cell growth and survival. Biochim Biophys Acta. 2003, 1603: 83-98.PubMed
4.
go back to reference Mayer MP, Brehmer D, Gassler CS, Bukau B: Hsp70 chaperone machines. Adv Protein Chem. 2001, 59: 1-44.CrossRefPubMed Mayer MP, Brehmer D, Gassler CS, Bukau B: Hsp70 chaperone machines. Adv Protein Chem. 2001, 59: 1-44.CrossRefPubMed
5.
go back to reference Weinstein IB: Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002, 297: 63-64. 10.1126/science.1073096.CrossRefPubMed Weinstein IB: Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002, 297: 63-64. 10.1126/science.1073096.CrossRefPubMed
6.
go back to reference Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF: Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res. 2001, 56: 127-155. 10.1210/rp.56.1.127.CrossRefPubMed Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF: Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res. 2001, 56: 127-155. 10.1210/rp.56.1.127.CrossRefPubMed
7.
go back to reference Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996, 87: 629-638. 10.1016/S0092-8674(00)81383-5.CrossRefPubMed Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996, 87: 629-638. 10.1016/S0092-8674(00)81383-5.CrossRefPubMed
8.
go back to reference Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA: Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003, 301: 94-96. 10.1126/science.1082015.CrossRefPubMed Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA: Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003, 301: 94-96. 10.1126/science.1082015.CrossRefPubMed
9.
go back to reference Jr JT, McCubrey JA: Targeting the Raf kinase cascade in cancer therapy - novel molecular targets and therapeutic strategies. Expert Opin Ther Targets. 2002, 6: 659-678.CrossRef Jr JT, McCubrey JA: Targeting the Raf kinase cascade in cancer therapy - novel molecular targets and therapeutic strategies. Expert Opin Ther Targets. 2002, 6: 659-678.CrossRef
10.
go back to reference Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature (London). 2002, 417: 949-954. 10.1038/nature00766.CrossRef Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature (London). 2002, 417: 949-954. 10.1038/nature00766.CrossRef
11.
go back to reference Cutress RI, Townsend PA, Brimmell M, Bateman AC, Hague A, Packham G: BAG-1 expression and function in human cancer. Br J Cancer. 2002, 87: 834-839. 10.1038/sj.bjc.6600538.CrossRefPubMedPubMedCentral Cutress RI, Townsend PA, Brimmell M, Bateman AC, Hague A, Packham G: BAG-1 expression and function in human cancer. Br J Cancer. 2002, 87: 834-839. 10.1038/sj.bjc.6600538.CrossRefPubMedPubMedCentral
12.
go back to reference Tybulewicz VLJ, Crawford CE, Jackson PK, Bronson RT, Mulligan RC: Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991, 65: 1153-1163. 10.1016/0092-8674(91)90011-M.CrossRefPubMed Tybulewicz VLJ, Crawford CE, Jackson PK, Bronson RT, Mulligan RC: Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991, 65: 1153-1163. 10.1016/0092-8674(91)90011-M.CrossRefPubMed
13.
go back to reference Kramer BW, Götz R, Rapp UR: Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer. 2004, 4: 24-10.1186/1471-2407-4-24.CrossRefPubMedPubMedCentral Kramer BW, Götz R, Rapp UR: Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer. 2004, 4: 24-10.1186/1471-2407-4-24.CrossRefPubMedPubMedCentral
14.
go back to reference Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulus T, Rapp UR: Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Diff. 2000, 11: 185-190.PubMed Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulus T, Rapp UR: Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Diff. 2000, 11: 185-190.PubMed
15.
go back to reference Takayama S, Reed JC, Homma S: Heat-shock proteins as regulators of apoptosis. Oncogene. 2003, 22: 9041-9047. 10.1038/sj.onc.1207114.CrossRefPubMed Takayama S, Reed JC, Homma S: Heat-shock proteins as regulators of apoptosis. Oncogene. 2003, 22: 9041-9047. 10.1038/sj.onc.1207114.CrossRefPubMed
16.
go back to reference Townsend PA, Cutress RI, Carroll CJ, Lawrence KM, Scarabelli TM, Packham G, Stephanou A, Latchman DS: BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome. J Biol Chem. 2004, 279: 20723-20728. 10.1074/jbc.M400399200.CrossRefPubMed Townsend PA, Cutress RI, Carroll CJ, Lawrence KM, Scarabelli TM, Packham G, Stephanou A, Latchman DS: BAG-1 proteins protect cardiac myocytes from simulated ischemia/reperfusion-induced apoptosis via an alternate mechanism of cell survival independent of the proteasome. J Biol Chem. 2004, 279: 20723-20728. 10.1074/jbc.M400399200.CrossRefPubMed
17.
go back to reference Rapp UR, Rennefahrt U, Troppmair J: Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim Biophys Acta. 2004, 1644: 149-158. 10.1016/j.bbamcr.2003.10.015.CrossRefPubMed Rapp UR, Rennefahrt U, Troppmair J: Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim Biophys Acta. 2004, 1644: 149-158. 10.1016/j.bbamcr.2003.10.015.CrossRefPubMed
18.
go back to reference Briknarova K, Takayama S, Brive L, Havert ML, Knee DA, Velasco J, Homma S, Cabezas E, Stuart J, Hoyt DW, Satterthwait AC, Llinas M, Reed JC, Ely KR: Structural analysis of BAG1 cochaperone and its interactions with Hsc70 heat shock protein. Nat Struct Biol. 2001, 8: 349-352. 10.1038/86236.CrossRefPubMed Briknarova K, Takayama S, Brive L, Havert ML, Knee DA, Velasco J, Homma S, Cabezas E, Stuart J, Hoyt DW, Satterthwait AC, Llinas M, Reed JC, Ely KR: Structural analysis of BAG1 cochaperone and its interactions with Hsc70 heat shock protein. Nat Struct Biol. 2001, 8: 349-352. 10.1038/86236.CrossRefPubMed
19.
go back to reference Sondermann H, Scheufler C, Schneider C, Höhfeld J, Hartl FU, Moarefi I: Structure of a Bag/Hsc70 complex: Convergent functional evolution of Hsp70 nucleotide exchange factors. Science. 2001, 291: 1553-1557. 10.1126/science.1057268.CrossRefPubMed Sondermann H, Scheufler C, Schneider C, Höhfeld J, Hartl FU, Moarefi I: Structure of a Bag/Hsc70 complex: Convergent functional evolution of Hsp70 nucleotide exchange factors. Science. 2001, 291: 1553-1557. 10.1126/science.1057268.CrossRefPubMed
Metadata
Title
BAG-1 haplo-insufficiency impairs lung tumorigenesis
Authors
Rudolf Götz
Boris W Kramer
Guadalupe Camarero
Ulf R Rapp
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2004
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-4-85

Other articles of this Issue 1/2004

BMC Cancer 1/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine